Other benefits include efficiency, cost reduction and enhanced data management, attributes that are important to any life sciences company. However, it can be challenging to provide the high level of security required in life sciences while also making the e-signature process easy to use. In the past, life sciences companies have had to use piecemeal solutions to signing – employing basic, less secure e-signature methods in areas where security was not vital and leaving regulated workflows to wet ink or complex technology. Yet, one digital signature company, SIGNiX, Inc., has challenged the statusquo. SIGNiX’s scalable, cost-effective solution is applicable across the entire security spectrum of transactions within life sciences, while retaining the ease-of use necessary for broad adoption. SIGNiX’s exceptional suitability to highly regulated verticals like pharma and life sciences is rooted in its ability to create and maintain legal evidence that is independent of SIGNiX.
The comprehensive audit trail attached to SIGNiX e-signatures provides independently verifiable evidence of the intent to sign along with information about when documents are viewed, when users are authenticated and more. Further, all documents and all versions of the documents are tamper evident. “Because the evidence backing a SIGNiX e-signature is embedded in the signed document, with no need to link back to SIGNiX, there is no expiration date on the e-signature. It can be validated in five, 10, 25 years or more,” said Jay Jumper, President and CEO of SIGNiX.
We offer a digital signature that is fully independent and meets U.S. and international regulations for FDA and EMA compliance
It also offers the option to insert a "qualified digital certificate," including a SAFE-BioPharma credential, for additional protection. The result of using this secure, compliant interface to expedite e-signatures can save hundreds of thousands of dollars in courier and paper costs, eliminate excessive resources, and reduce storage needs and delays in finalizing transactions.
Consider the results from Sarah Cannon Research Institute, which chose SIGNiX to speed up clinical trials by enabling doctors to sign regulatory forms electronically and receive automated reminders to accelerate the signing process. By switching to SIGNiX, the research institute eliminated the need to ship at least 40,000 documents each year using next-day mail, resulting in dramatic savings in time and money. “Our success is tied to the superiority of our e-signature solutions. The market for e-signatures is growing, and independent, evidence-based security will be the most important criteria in life sciences in e-signing in the future,” Jumper concluded.